DoD Lung Cancer Research Program funding opportunities for FY23

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

NCI announced that the paylines for R01 grants for established and new investigators are expected to drop to the 4th percentile—a historic low for the institute.

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

A study published today by researchers at the Translational Genomics Research Institute, part of City of Hope, and clinician-scientists at Baylor Scott & White Research Institute revealed a potential new therapeutic strategy for fighting lung cancer that harnesses one of the body’s immune cells, natural killer cells.

July 25, 2025

Vol.51 No.29

Drugs & Targets

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

FDA granted Breakthrough Therapy designation to elironrasib, a RAS(ON) G12C-selective inhibitor, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and immunotherapy but have not been previously treated with a KRAS G12C inhibitor.

July 25, 2025

Vol.51 No.29

Podcast The Directors

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

“I don’t think any good cancer center director would be worth their weight in salt if they weren’t worried about something at night,” said Mark Evers, director of University of Kentucky Markey Cancer Center.

July 18, 2025

Vol.51 No.28

By Paul Goldberg and Katie Goldberg

DoD Lung Cancer Research Program funding opportunities for FY23

YOU MAY BE INTERESTED IN

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

Renew today!

Subscriber content

Never miss an issue!

Login

DoD Lung Cancer Research Program funding opportunities for FY23

YOU MAY BE INTERESTED IN

FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts

Tagrisso + chemo improve OS in EGFR-mutated advanced lung cancer, phase III trial shows

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Study reveals immune-based therapy that may be effective in hard-to-treat lung cancers

FDA grants Breakthrough Therapy designation to elironrasib for lung cancer

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentumAs oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic

Never miss an issue!

Login

The Directors: Mark Evers and Steven Libutti on riding out the tempest—and maintaining research momentum
As oncology braces for funding, Medicaid cuts, these two directors tell young investigators not to panic